Sign inJoin waitlistJoin the waitlist

Chloe Atreya

Professor In Residence · University of California (San Francisco) School of Medicine

Credentials: · · · · ·

History

University of California (San Francisco) School of Medicine
Present

Yale University
2009–2011
University of California (San Francisco) School of Medicine
2008–2009
Internal Medicine
University of Washington School of Medicine
2005–2008
Yale University
Yale School of Medicine
2001–2005
Princeton University
1994–1998
Princeton University
1995–1998

Research

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Journal of Clinical Oncology · 2020 · 801 citations
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
Cancer Discovery · 2018 · 499 citations
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Journal of Clinical Oncology · 2015 · 434 citations

Alan Venook
31 papers
Katherine Van Loon
27 papers · 1 as a fellow
SP
Sorbarikor Piawah
11 papers
Wes Kidder
11 papers · 1 as a fellow
Kate Kelley
9 papers
Andrew Ko
7 papers
RC
Ryan Corcoran
7 papers
Anand Dhruva
6 papers
Jeffrey Meyerhardt
6 papers
Than Kyaw
6 papers
Emily Bergsland
5 papers
Robert Warren
5 papers

Grants

Kinome-Guided Targeting of Cooperative Dependencies in BRAF Mutated Colorectal Cancer
National Cancer Institute · R01
Contact PI · $4.1M · University of California, San Francisco
2019–2029
(PQ10) Harnessing the Human Gut Microbiome to Predict Chemotherapy Outcomes
National Cancer Institute · R21
PI · $378K · University of California, San Francisco
2018–2021
Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer Models
National Cancer Institute · K08
Contact PI · $866.7K · University of California, San Francisco
2013–2019

Clinical trials

Yoga to Improve Disparities in Cancer Survivorship
Principal investigator · Completed
University of California, San Francisco
2025–2026
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
Principal investigator · Terminated · Phase 1
University of California, San Francisco
2020–2022
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
Principal investigator · Terminated · Phase 2
Chloe Atreya, MD, PhD
2019–2025
Web-based Mindfulness Meditation in Reducing Distress in Participants With Metastatic Gastrointestinal Cancer and Their Caregivers
Principal investigator · Completed
University of California, San Francisco
2018–2019